The use of TPGS in drug delivery systems to overcome biological barriers

Página do item simplificado
dc.contributor.authorTavares Luiz, Marcela
dc.contributor.authorDelello Di Filippo, Leonardo [UNESP]
dc.contributor.authorCarolina Alves, Renata [UNESP]
dc.contributor.authorSousa Araújo, Victor Hugo [UNESP]
dc.contributor.authorLobato Duarte, Jonatas [UNESP]
dc.contributor.authorMaldonado Marchetti, Juliana
dc.contributor.authorChorilli, Marlus [UNESP]
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2021-06-25T11:07:06Z
dc.date.available2021-06-25T11:07:06Z
dc.date.issued2021-01-05
dc.description.abstractNanotechnology has been applied in the medicine field to improve the treatment of a wide range of diseases. However, to reach the nanomedicines delivery to desirable target tissue for promote an enhancement of pharmacological activity, these nanomedicines must overcome biological barriers, such as mucus gel, skin, corneal and blood–brain barriers. Aiming the increase nanomedicines permeation through these barriers, surface modifications of nanocarriers with permeation enhancers and/or specific ligands for cellular receptors have been widely investigated. Among these modifications, d-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS) is a biocompatible macromolecule that has been evaluated as a permeation enhancer. TPGS is a non-ionic surfactant composed by the natural vitamin E bonded with polyethylene glycol 1000 (PEG) and its composition have been responsible to enhance cellular internalization and permeation of nanomedicines through biological barriers. In addition, this molecule has acted as solubilizer, emulsifier, stabilizer and P-glycoprotein (P-gp) inhibitor, that are important features to manufacture nanomedicines with suitable to overcome barriers and multidrug resistance (MDR) mechanisms. This review will address the TPGS physicochemical and biological features and its most recent application in nanomedicine field to overcome biological barriers.en
dc.description.affiliationSchool of Pharmaceutical Science of Ribeirao Preto University of Sao Paulo (USP), Ribeirao Preto
dc.description.affiliationSchool of Pharmaceutical Science of Sao Paulo State University (UNESP), Araraquara
dc.description.affiliationUnespSchool of Pharmaceutical Science of Sao Paulo State University (UNESP), Araraquara
dc.identifierhttp://dx.doi.org/10.1016/j.eurpolymj.2020.110129
dc.identifier.citationEuropean Polymer Journal, v. 142.
dc.identifier.doi10.1016/j.eurpolymj.2020.110129
dc.identifier.issn0014-3057
dc.identifier.scopus2-s2.0-85096094072
dc.identifier.urihttp://hdl.handle.net/11449/208145
dc.language.isoeng
dc.relation.ispartofEuropean Polymer Journal
dc.sourceScopus
dc.subjectBlood brain barrier
dc.subjectCorneal barrier
dc.subjectd-α-Tocopheryl polyethylene glycol 1000 succinate
dc.subjectMucus gel barrier
dc.subjectNanotechnology
dc.subjectSkin barrier
dc.titleThe use of TPGS in drug delivery systems to overcome biological barriersen
dc.typeResenha

Arquivos

Coleções

Artigos - Fármacos e Medicamentos - FCFAR